Citius Oncology Secures Up to $36.5M in Critical Debt and Equity Financing to Extend Runway

summarizeSummary

Citius Oncology has secured up to $36.5 million in new capital through a warrant inducement transaction and a senior secured term loan, providing a crucial financial lifeline for the company which previously faced going concern doubts.

check_boxKey Events

• Secured Significant Capital

  The company secured up to $36.5 million in new capital, including an immediate $21.5 million cash infusion. This comprises $11.5 million from a warrant inducement transaction and an initial $10 million tranche from a senior secured term loan.

• Warrant Inducement Details

  A holder exercised 12,777,778 existing warrants at a reduced price of $0.90 per share, generating $11.5 million in gross proceeds. In return, the company issued 25,555,556 new unregistered warrants at an exercise price of $0.90, exercisable upon stockholder approval.

• Senior Secured Term Loan Facility

  An initial $10 million was funded from a new senior secured term loan facility of up to $25 million, with two additional tranches totaling $15 million available upon achieving revenue and liquidity milestones. The loan bears interest at a variable rate (minimum 12.75%) and matures in November 2029.

• Parent Debt Subordination & Conversion

  The company's $3.8 million promissory note to its parent, Citius Pharmaceuticals, Inc., was subordinated to the new senior debt. The parent now has a voluntary option to convert the principal into common stock at $0.90 per share.

auto_awesomeAnalysis

This comprehensive financing package is a critical development for Citius Oncology, directly addressing the substantial doubt about its ability to continue as a going concern, which was projected to run out of cash by May 2026. The immediate infusion of $21.5 million, with potential for an additional $15 million, provides a vital lifeline and extends the company's operational runway. While the transactions involve significant potential dilution through the issuance of new warrants and conversion options, the ability to secure such substantial capital, especially following a Nasdaq delisting notice, is a strong positive signal for the company's near-term viability. The funds are earmarked for the commercialization of LYMPHIR, which recently saw its initial shipment to Europe, indicating a strategic focus on revenue generation. Investors should monitor the company's progress in achieving the milestones required for the additional loan tranches and the impact of the dilution on the stock price. This filing finalizes the terms and pricing of the offering initiated on May 5, 2026.